Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Inclusion Criteria: * Ohio State University patients \> 18 years old * Diagnosis of ≥ 1cm keratinocyte carcinoma, accessible by intra-tumoral injection * Confirmation of cutaneous SCC (cSCC) (10 patients total) or BCC (10 patients total) via diagnostic biopsy * BCC: Nodular or aggressive subtype * SCC: Well-differentiated or aggressive subtype with T1 or T2 staging by American Joint Committee on Cancer (AJCC) criteria * Patient meets criteria for standard of care surgical treatment with either wide local excision or Moh's surgery * Presence of residual clinical cancer ≥ 1cm at the time of baseline * Willingness to follow up for residual cancer extirpation between 2-8 weeks after the injection Exclusion Criteria: * Planned or concurrent radiation or systemic treatment for solid tumor or hematologic malignancy including chemotherapies or immunotherapies received within 6 weeks of trial enrollment. These include but are not limited to methotrexate, 5-fluorouracil, vismodegib, cepilimumab, pembrolizumab, nivolumab, ipilimumab for any skin malignancy * \< 18 years old * A negative deep and peripheral margin status from the diagnostic biopsy * Diagnostic biopsy with the following histopathologic characteristics: * BCC: Superficial subtype * SCC: SCC in situ (SCCIS)/Bowen disease, basosquamous, keratoacanthoma (KA)-type SCC, or tumor with \> T2 staging by AJCC criteria * Any skin disease or active infection in the same area that may confound assessments * Inability to f…